How well does the capillary thyroid-stimulating hormone test for newborn thyroid screening predict the venous free...

Area of Science:

• Neonatal endocrinology
• Pediatric thyroid disorders
• Newborn screening

Background:

• Elevated capillary thyroid-stimulating hormone (TSH) in newborns requires prompt evaluation.
• Distinguishing between permanent and transient hypothyroidism is crucial for appropriate management.
• Timely initiation of levothyroxine (L-T4) treatment is vital for neurodevelopmental outcomes.

Purpose of the Study:

• To establish a capillary TSH threshold for predicting subnormal venous free thyroxine (fT4) in newborns.
• To identify infants who may not require immediate L-T4 treatment pending further testing.
• To optimize the diagnostic pathway for neonatal hypothyroidism.

Main Methods:

• Retrospective analysis of infants in Scotland with elevated capillary TSH since 1979.
• Focus on AutoDELFIA assay screening data from 2002-2013.
• Correlation analysis between capillary TSH and venous fT4 levels.

Main Results:

• A strong negative correlation was observed between capillary TSH and venous T4 (Spearman's rho = -0.707).
• An optimal capillary TSH threshold of >40 mU/L predicted venous fT4 <10 pmol/L with 90.3% sensitivity and 65.9% specificity.
• Of 93 infants with capillary TSH ≤40 mU/L, only 15 (9.7%) had venous fT4 <10 pmol/L.

Conclusions:

• A capillary TSH level ≤40 mU/L in newborns may warrant deferral of L-T4 treatment.
• Venous thyroid function tests (TFTs) are essential for confirming diagnosis.
• Prompt availability of venous TFT results is critical when deferring treatment.